ALPHARETTA, Ga., Nov. 5, 2015 /PRNewswire/ -- EndoChoice Holdings, Inc. (NYSE: GI) announced today that it has entered a strategic partnership with De Lage Landen Financial Services, Inc. of Wayne, PA (DLL) to provide a new financing program for EndoChoice customers in the United States. The new program, known as EndoChoice Capital, will provide flexible lease financing for the Fuse endoscopy systems and other products and services sold directly by EndoChoice. EndoChoice Capital will be supported by dedicated sales and credit teams that will assist customers with their ongoing financing needs.
"EndoChoice Capital will expand financing options available to our customers and strengthen our overall position in the marketplace. We will now be able to provide a comprehensive package of products, services and financing options and distribute those options in a seamless way to our customers," said David N. Gill, Chief Financial Officer of EndoChoice.
"With more than 50 years of experience providing tailored leasing solutions to some of the largest and most successful medical equipment companies, DLL has the expertise to provide EndoChoice customers with comprehensive financing solutions, plus best-in-class service," Gill said. "DLL has extensive experience in the diagnostic imaging and surgical equipment markets and has formed similar financing programs with several other health care equipment manufacturers."
This press release contains "forward-looking statements" as defined under U.S. federal securities laws, including, among other things, statements about our expected future financial performance.
Forward-looking statements include all statements that are not historical facts. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on any forward-looking statements in this press release. Factors that could affect these statements include, but are not limited to, our ability to achieve or sustain profitability; general economic, market, or business conditions; the opportunities that may be presented to and pursued by the Company; conditions in the medical technology industry; the ability to generate sufficient cash flow or otherwise obtain funds to repay new or outstanding indebtedness; the ability to successfully commercialize our products, including Fuse®; competition from new or existing competitors; and other risks described from time to time in EndoChoice's filings with the Securities and Exchange Commission ("SEC") (including the prospectus filed by EndoChoice with the SEC on June 5, 2015). The discussion of these risks is specifically incorporated by reference into this press release.
Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control or are currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our expectations and projections. Except as required by law, we disclaim any obligation to update any forward-looking statements for any reason after the date of this press release.
Based near Atlanta, EndoChoice (NYSE: GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries. The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy System (Fuse®). EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice Holdings, Inc.
About DLL: DLL is a global financial solutions partner working in Agriculture, Food, Healthcare, Clean Technology, Automotive, Transportation, Construction, Industrial Equipment and Office Technology. We collaborate with equipment manufacturers, dealers and distributors to enable businesses to obtain and use the assets they need to contribute meaningfully to the world. DLL delivers original, integrated financial solutions to support the asset life cycle from leasing, vendor and commercial finance to remarketing. In addition, we offer mobility solutions, factoring and consumer finance. DLL's 5,500 members support its partners in more than 35 countries. The company is a fully owned subsidiary of Rabobank Group. www.dllgroup.com.
Company Contact: David Gill, Chief Financial Officer firstname.lastname@example.org 678-585-1040
SOURCE EndoChoice Holdings, Inc.